Novartis distances itself from Pixuvri
This article was originally published in Scrip
Executive Summary
Novartis will not be exercising its option for Cell Therapeutics' non-Hodgkin's lymphoma drug Pixuvri (pixantrone), which it has held since 2006, despite the product finally winning round Europe's reimbursement authorities. It is also returning rights to Opaxio (paclitaxel poliglumex), which it acquired under the same agreement (scripintelligence.com, 22 September 2006). Novartis has failed to show any real interest in either drug since signing the deal.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.